ArticlePloS one2009
p63 promotes cell survival through fatty acid synthase.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- p63 affects distinct metabolic pathways during keratinocyte senescence, evaluated by metabolomic profile and gene expression analysis.Cell death & disease · 2024Article
- p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.Cell reports. Medicine · 2024Article
- Article
- Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma.Lipids in health and disease · 2022Article
- Acetyl-CoA-mediated autoacetylation of fatty acid synthase as a metabolic switch of de novo lipogenesis inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Metabolic regulation of the neural stem cell fate: Unraveling new connections, establishing new concepts.Frontiers in neuroscience · 2022Review
- Post-Translational Modifications That Drive Prostate Cancer Progression.Biomolecules · 2021Review
- The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy.British journal of cancer · 2017Review
- Article
- Two-way communication between the metabolic and cell cycle machineries: the molecular basis.Cell cycle (Georgetown, Tex.) · 2015Review
- SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.The Journal of clinical investigation · 2014Article
- Metabolic regulation by p53 family members.Cell metabolism · 2013Review
- Phospho-ΔNp63α/SREBF1 protein interactions: bridging cell metabolism and cisplatin chemoresistance.Cell cycle (Georgetown, Tex.) · 2012Article
- Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger?Biochimica et biophysica acta · 2012Review
- DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation.The Journal of biological chemistry · 2011Article
- DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation.Cancer research · 2011Article
- A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.Breast cancer research : BCR · 2011Article
- Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.Breast cancer research : BCR · 2010Article
- Article
Corrections and comments
- Expression of concern · 2019-07-11Concerns/Issues about Data · Duplication of/in Image ·
- Expression of concern
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
There is increasing evidence that p63, and specifically DeltaNp63, plays a central role in both development and tumorigenesis by promoting epithelial cell survival. However, few studies have addressed the molecular mechanisms through which such important function is exerted. Fatty acid synthase (FASN), a key enzyme that synthesizes long-chain fatty acids and is involved in both embryogenesis and cancer, has been recently proposed as a direct target of p53 family members, including p63 and p73. Here we show that knockdown of either total or DeltaN-specific p63 isoforms in squamous cell carcinoma (SCC9) or immortalized prostate epithelial (iPrEC) cells caused a decrease in cell viability by inducing apoptosis without affecting the cell cycle. p63 silencing significantly reduced both the expression and the activity of FASN. Importantly, stable overexpression of either FASN or myristoylated AKT (myr-AKT) was able to partially rescue cells from cell death induced by p63 silencing. FASN induced AKT phosphorylation and a significant reduction in cell viability was observed when FASN-overexpressing SCC9 cells were treated with an AKT inhibitor after p63 knockdown, indicating that AKT plays a major role in FASN-mediated survival. Activated AKT did not cause any alteration in the FASN protein levels but induced its activity, suggesting that the rescue from apoptosis documented in the p63-silenced cells expressing myr-AKT cells may be partially mediated by FASN. Finally, we demonstrated that p63 and FASN expression are positively associated in clinical squamous cell carcinoma samples as well as in the developing prostate. Taken together, our findings demonstrate that FASN is a functionally relevant target of p63 and is required for mediating its pro-survival effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.